According to GlobalData’s medical device pipeline database, 344 Contrast Agents devices are in various stages of development globally. GlobalData’s report provides an overview of the segment’s pipeline landscape and offers detailed analysis of its products. Buy the report here.
Smarter leaders trust GlobalData
Of these devices, 205 are in active development, while the remaining 144 are in an inactive stage of development. There are 124 products in the early stages of development, and the remaining 81 are in the late stages of development.
Contrast agents are substances applied in medical imaging to increase visibility of internal structures like organs, blood vessels, and other tissues Before the imaging operation, they are frequently injected into the body or taken orally to boost contrast and enhance the visibility of specific structures. The contrast agents market includes computed tomography (CT) contrast agents, magnetic resonance imaging (MRI) contrast agents and ultrasound contrast agents (microbubbles). One unit of imaging agent is dependent on the type of agent and procedure for which it is used. One unit refers to the average dose of each computed tomography (CT) contrast agent/magnetic resonance imaging (MRI) contrast agent/ultrasound contrast agent, ranging from 067mL/procedure to 1054mL/procedure.
Innovations in the medical devices sector are linked to the development of new approaches, processes, or technologies for treating, diagnosing, and managing disease in response to demand from healthcare for better patient outcomes and reduce healthcare costs.
Based on an analysis of GlobalData’s Medical Intelligence Center pipeline product database, these actively developed Contrast Agents pipeline devices are all expected to be approved within the next ten years.
Currently, private organizations, public entities and institutions are working on the development of Contrast Agents devices. Overall, most of these Contrast Agents pipeline devices are being developed by private entities.
Key players involved in the active development of Contrast Agents include Inlighta Biosciences, Edinburgh Molecular Imaging, Precision Molecular, MediBeacon, Microvascular Therapeutics, 3B Pharmaceuticals, Amydis, Vanderbilt University, Voyageur Pharmaceuticals and NuvOx Pharma.
For a complete picture of the developmental pipeline for Contrast Agents devices, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
The medical devices pipeline data used in this article were obtained from the Medical Pipeline Products Database of GlobalData’s Medical Intelligence Center. The Pipeline Products database is a is a comprehensive source of information on medical devices, it covers 39K products which are in development stage and intended for diagnosis, treatment, and management of diseases/conditions/symptoms directly or indirectly. The pipeline products included in the database are sourced from reliable and authenticated sources, such as company websites, SEC filings, conference presentations, analyst presentations, news releases, clinical trial registries, and grants. The information is collected by following systematic research techniques and proprietary methodology.
